Slide 1: Financial results Full year 2024 (preliminary)
Financial results Full year 2024 (preliminary) — Dr. Jean-Yves Parisot (CEO), Olaf Klinger (CFO) 30 January 2025
Slide 2: Agenda
Agenda Overview — 01 02 03 2024 Financials Market trends, Strategy, at a Glance 2024 Outlook 2 2
Slide 3: 2024 at a glance
01 2024 at a glance 3
Slide 4: Financial highlights FY 2024
Financial highlights FY 2024 Strong recovery of profitability / Double-digit growth in bottom-line figures — Sales Business Free Cash Flow1 Capex €4,999m +8.7% €680m €231m (2023: €4,730m) organic growth 13.6% of sales 4.6% of sales +5.7% in reporting currency EBITDA Net Income 3 Net debt €1,033m 20.
Slide 5: Sales 2024: Strong organic growth
Sales 2024 Strong organic growth — Symrise Group In €m (sales growth in %) +8.7% organic sales growth through diversified portfolio +8.7% organic growth +5.7% reporting currency €104m negative FX-effect 4,730 4,999 €38m negative impact from divestiture of beverage trading business in UK 2023 2024 5
Slide 6: Sales by Segment 2024
Sales by Segment 2024 Both Segments with high organic growth rates — Taste, Nutrition & Health in €m / organic growth in % Scent & Care in €m / organic growth in % 3,091 1,908 2024 2,978 1,752 2024 2023 2023 +7.8% +10.2% +3.8 %* +8.9 %* Growth driven by Fragrance with continued high growth momentum,
Slide 7: Sales by Region in 2024
Sales by Region in 2024 Double-digit organic growth in Latin America and EAME — Sales by region Organic growth by region % of global sales in % €1,277m 26 % €1,035m NA 21 % North America Asia/Pacific APAC +1.5% +9.3% EAME +10.9% €1,992m Latin America 40 % +15.2% EAME €695m 14 % LATAM 7
Slide 8: Strong financial track record
Strong financial track record Successful EBITDA turnaround in 2024 — Growth and profitability since IPO Sales and EBITDA in €m EBITDA 23% 21,1% 21,9% 21,5% 20,6% 21,3% margin 21,3% 20,0% 22,0% 21,0% 20,7% 21,1% 20,0%2 corridor 20,4% 19,8% 19,9% 20,0% 20% 18,0% 19,5% 19,1%3 Sales CAGR ~8.1% 4.999 4,6
Slide 9: Financials in detail
02 Financials in detail 9
Slide 10: Group 2024: Organic growth of 8.7%
Group 2024 Organic growth of 8.7% (reported 5.7%) — Sales development FY 2024 In €m +8.7% Organic growth of 8.7% in 2024; Without the impact of +8.1% +0.6% -0.8% -2.2% +5.7% hyperinflation, organic growth of 8.1% in 2024 26 -38 4,999 Negative sales contribution in FY 2024 from portfolio effect of 38
Slide 11: Group profitability 2024
Group profitability 2024 EBITDA increase of +160bps to 20.7% — Change 1 in € million FY 2023 FY 2023 FY 2024 in % Sales 4,730 4,730 4,999 5.7 Gross profit 1,693 1,739 1,963 12.9 Double digit growth of Gross profit, EBITDA and EBIT Gross profit margin in % 35.8 36.8 39.3 250bps EBITDA 852 903 1,033 1
Slide 12: Symrise efficiency program
Symrise efficiency program Total savings of €50m in FY 2024 achieved — 2024 dedicated initiatives First lasting efficiencies out of ONE SYM program − Implemented a cost-conscious culture − Executed hiring freeze − Consolidation of expertise − Thorough use of saving potential, e.g. Active cost − Leve
Slide 13: Taste, Nutrition & Health FY 2024
Taste, Nutrition & Health FY 2024 Healthy growth and strong profitability Short P&L — In €m Sales development in € million FY 20231 FY 2024 Change in % In €m EBITDA 626.8 686.4 9.5 EBITDA margin in % 21.0 22.2 +7.8% -1.3% -2.7% EBIT 426.4 463.5 8.7 +3.8% EBIT margin in % 14.3 15.0 -38 -81 231 Organi
Slide 14: Scent & Care FY 2024
Scent & Care FY 2024 Double-digit growth with strong business in Fragrance — Short P&L In €m in € million FY 20231 FY 2024 Change in % Sales development EBITDA 276.7 347.0 25.4 In €m EBITDA margin in % 15.8 18.2 EBIT 184.8 254.4 37.7 EBIT margin in % 10.5 13.3 +10.2% 0.0% -1.3% +8.9% 0 Organic growt
Slide 15: EPS: Increase of 40.5% to €3.42
EPS Increase of 40.5 % to €3.42 — Change in € million FY 2023 FY 2024 in % EBIT 559 718 28.3 Financial Result -94 -72 23.7 Financial result: improved by €22m, mainly due to lower interest expenses in connection with financing as well as interest on pension EBT 465 646 38.9 provisions and lower net l
Slide 16: Working capital and Capex
Working capital and Capex Clearly defined actions and measures to reach mid-term targets — Net WoC Trade Receivables Inventories Trade Payables Net WoC Capex as % of 34.6% 34.4% as % of 5.7% 4.6% LTM sales sales 1,635 1,717 868 938 1,256 1,283 -489 -504 FY 2023 FY 2024 FY 2023 FY 2024 Measures: Inve
Slide 17: Business Free Cash Flow (BFCF)
Business Free Cash Flow (BFCF) Strong improvement with BFCF of 13.6 % — BFCF as % of sales FY 2024 BFCF of €680m = 13.6% of sales significantly improved vs. PY 16.0% (FY 20231: €553m = 11.7% of sales) 14.1% 13.6% 12.7% 11.7% Strong operating performance Slight decrease in CAPEX from €270m in FY 2023
Slide 18: Net debt development
Net debt development Reduction of net debt incl. pensions leads to leverage of 2.3 x EBITDA — Acquisitions of Schaffelaarbos, Néroli & Romani, Net debt / EBITDA(N) Wing Biotechnology Status Quo ADF/IDF + Pinova capital increase and increased stake in Net debt including pension provisions and acquisi
Slide 19: Market trends, Strategy, Outlook
03 Market trends, Strategy, Outlook 19
Slide 20: Key market trends
Key market trends Well-aligned business portfolio and product offering driven by key megatrends — Humans • Prioritized holistic well-being and preventive health of GenZ expect their CPGs to have • Healthy aging populations – life-span vitality 74% holistic care solutions inbuilt • New generations wi
Slide 21: Our transformational journey towards a sustainable performance
Our transformational journey towards a sustainable performance Being — and staying unique Unleashing the full beauty of ONE Symrise Strategy ONE Symrise ➢ The power of ONE Symrise: creating more value for all our stakeholders, and ultimately improving our financial performance ➢ The power of ONE inn
Slide 22: Cross-fertilizing for a unique ONE CARE
Cross-fertilizing for a unique “ONE CARE” Leveraging synergies between S&C and TN&H — We deliver better living through scent We make life taste better and healthier Key product trends in Scent & Care Taste, Nutrition & Health holistic health, well-being & beauty Cosmetic Health Active “ONE CARE” Mov
Slide 23: Outlook 2025
Outlook 2025 Confident to achieve ambitious targets — Corporate view Business environment fully intact with Organic growth Profitability Business Free Cash Flow EBITDA margin % of sales high industry dynamics Taste, Nutrition & Health Building competencies towards complementary business areas Scent
Slide 24: Mid-term financial objectives
Mid-term financial objectives Symrise specifies 2028 financial targets — Financial targets Mid-term until 2028 Organic sales growth (CAGR) 5 – 7% EBITDA margin 21 – 23% Business Free Cash Flow >14% Contribution from M&A as an additional topline driver Focus on opportunities that add value in terms o
Slide 25: We are well positioned to achieve our targets
We are well positioned… …to achieve our short-, mid- and long-term targets — Unique position Transformation Continued Focus on Further with a well- enablers to support investments working capital acquisitions balanced portfolio growth, efficiency into capacity management will offer new and sustainab
Slide 26: Symrise: always inspiring more
ry symrise always inspiring more
Slide 27: Financial calendar 2025 and Contact
Symrise AG — Financial calendar 2025 Contact Symrise AG 27 March 30 July Muehlenfeldstraße 1 Company report 2024 H1 2025 Financial results 37603 Holzminden, Germany 29 April 28 October Rene Weinberg Q1 Trading statement 9M 2025 Trading statement Investor Relations rene.weinberg@symrise.com 20 Mai An
Slide 28: Back-up
— Back-up External • Copyright® 2024 28
Slide 29: Hyperinflation impact on organic growth
Hyperinflation impact on organic growth One-off effect on Q4 organic growth by conversion into reporting currency — Devaluation of Argentine peso.. …leading to a negative Q4 conversion impact… ..reducing FY24 overall growth Illustrative example based on artificial numbers YTD Sep 24 Total 5.9% EUR /